Skip to main
ABEO

Abeona Therapeutics (ABEO) Stock Forecast & Price Target

Abeona Therapeutics (ABEO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Abeona Therapeutics Inc. is projected to achieve approximately $32 million in top-line revenue for 2025, with expectations of a substantial increase to $130.4 million in 2026, indicating strong growth potential. The market access situation for the company appears favorable, suggesting the possibility of improved coverage and further revenue enhancements in the near term. Additionally, the robust pipeline of gene therapies aimed at addressing unmet medical needs could provide additional upside to the company's financial forecasts.

Bears say

Abeona Therapeutics Inc faces significant risks that contribute to a negative outlook, particularly regarding the potential slower than anticipated market uptake of its flagship product, pz-cel, in the United States. Additionally, the company may struggle to optimize the value of pz-cel in international markets, compounded by the possibility of setbacks in their earlier-stage pipeline programs, which could further hinder revenue growth. Furthermore, there exists a long-term dilution risk that could adversely affect shareholder value and financial stability.

Abeona Therapeutics (ABEO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abeona Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abeona Therapeutics (ABEO) Forecast

Analysts have given Abeona Therapeutics (ABEO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Abeona Therapeutics (ABEO) has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abeona Therapeutics (ABEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.